Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Magdalena Kovacsovics-Bankowski"'
Autor:
Siwen Hu-Lieskovan, Ngan Nguyen, Magdalena Kovacsovics-Bankowski, John Hyngstrom, Li-Chun Cheng, Jordan P McPherson, Umang Swami, Matthew H Spitzer, Johanna M Sweere, Connor P Healy, Natalia Sigal, William D Chronister, Shane A Evans, John Marsiglio, Berit Gibson, Alyssa Erickson-Wayman, Yoko S Derose, Annaleah Larson Eliason, Carlos O Medina, Ramji Srinivasan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed.
Externí odkaz:
https://doaj.org/article/33adf4f87d5845b590a6128eac8e0678
Autor:
John Marsiglio, Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami, Douglas Grossmann, Alyssa Erickson-Wayman, Heloisa P. Soares, Katie Kerrigan, Berit Gibson, Jennifer Anne Doherty, John Hyngstrom, Sheetal Hardikar, Siwen Hu-Lieskovan
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundType 1 diabetes mellitus (T1DM) is a rare, but serious immune-related adverse event (irAE) of immune checkpoint inhibitors (ICIs). Our goal was to characterize treatment outcomes associated with ICI-induced T1DM through analysis of clinical
Externí odkaz:
https://doaj.org/article/33e51152bcc24a469b71e51e480b2741
Autor:
Antoni Ribas, John M. Kirkwood, Larissa A. Korde, Elad Sharon, Nageatte Ibrahim, Sama Ahsan, Scot W. Ebbinghaus, Krishna S. Gunturu, Magdalena Kovacsovics-Bankowski, Brian Gastman, Zeynep Eroglu, James Moon, Hongli Li, Douglas B. Johnson, Ragini R. Kudchadkar, Bartosz Chmielowski, Robert M. Conry, Karl D. Lewis, Pauline Funchain, Kari Kendra, Elizabeth I. Buchbinder, Justine V. Cohen, Nikhil I. Khushalani, Thach-Giao Truong, Teresa M. Petrella, Michael V. Knopp, Vernon K. Sondak, Ahmad A. Tarhini, Sapna P. Patel, Megan Othus, Kenneth F. Grossmann
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70860ad8a591df39f1504fb8bc1ae75a
https://doi.org/10.1158/2159-8290.22541236.v1
https://doi.org/10.1158/2159-8290.22541236.v1
Autor:
Andrew D. Weinberg, Walter J. Urba, Rachel Sanborn, Eric Bernstein, Todd Crocenzi, Tracy Kelly, Nicole Rymarchyk, Laurie Delanty-Miller, Brenda Fisher, Todd Coffey, Daniel Haley, William Miller, Tarsem Moudgil, Bernard A. Fox, Tanisha Meeuwsen, Iliana Gonzalez, Joshua Walker, Kevin Floyd, Lana Chisholm, Edwin Walker, Nicholas Morris, Magdalena Kovacsovics-Bankowski, Brendan D. Curti
PDF file - 198K, Figure 1. Characterization of the anti-OX40 mAb (9B12). Figure 2. Total peripheral lymphocyte counts. Figure 3. Pharmacokinetics of CD134 (anti-OX40) mAb in patients. Figure 4. Direct ex vivo detection of the murine anti-OX40 mAb bou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a41e5e36637b2791e2e9f3b27e2fcfa7
https://doi.org/10.1158/0008-5472.22396172
https://doi.org/10.1158/0008-5472.22396172
Autor:
Andrew D. Weinberg, Walter J. Urba, Rachel Sanborn, Eric Bernstein, Todd Crocenzi, Tracy Kelly, Nicole Rymarchyk, Laurie Delanty-Miller, Brenda Fisher, Todd Coffey, Daniel Haley, William Miller, Tarsem Moudgil, Bernard A. Fox, Tanisha Meeuwsen, Iliana Gonzalez, Joshua Walker, Kevin Floyd, Lana Chisholm, Edwin Walker, Nicholas Morris, Magdalena Kovacsovics-Bankowski, Brendan D. Curti
PDF file - 68K, Details clinical trial, flow cytometry and monkey experiments referred to in the manuscript.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af937245e48fa5db923238ab0d0d5e4
https://doi.org/10.1158/0008-5472.22396169
https://doi.org/10.1158/0008-5472.22396169
Autor:
Brian R. Gastman, Ahmad A. Tarhini, Robert M. Conry, Pauline Funchain, Karl D. Lewis, Antoni Ribas, Sapna Pradyuman Patel, Hongli Li, Kenneth F. Grossmann, Magdalena Kovacsovics-Bankowski, Teresa M. Petrella, Elizabeth I. Buchbinder, Nageatte Ibrahim, Ragini R. Kudchadkar, James Moon, Douglas B. Johnson, Thach-Giao Truong, Larissa A. Korde, Michael V. Knopp, Kari Kendra, Elad Sharon, Scot Ebbinghaus, Bartosz Chmielowski, Vernon K. Sondak, John M. Kirkwood, Zeynep Eroglu, Nikhil I. Khushalani, Justine V. Cohen, Megan Othus, Krishna S Gunturu, Sama Ahsan
Publikováno v:
Cancer discovery, vol 12, iss 3
Cancer Discov
Cancer Discov
We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be95c3ea01eedee0bb4c9a85fc5d89b2
https://escholarship.org/uc/item/8x51z8rb
https://escholarship.org/uc/item/8x51z8rb
Autor:
Walter J. Urba, Rachel E. Sanborn, Lana Chisholm, Nicholas P. Morris, Bernard A. Fox, Tarsem Moudgil, Kevin Floyd, Andrew D. Weinberg, Iliana Gonzalez, Joshua M. Walker, Brenda Fisher, Daniel Haley, Eric D. Bernstein, Edwin B. Walker, Nicole Rymarchyk, Tracy L Kelly, Tanisha Meeuwsen, Laurie Delanty-Miller, Todd S. Crocenzi, Magdalena Kovacsovics-Bankowski, Brendan D. Curti, Todd Coffey, William Miller
Publikováno v:
Cancer Research. 73:7189-7198
OX40 is a potent costimulatory receptor that can potentiate T-cell receptor signaling on the surface of T lymphocytes, leading to their activation by a specifically recognized antigen. In particular, OX40 engagement by ligands present on dendritic ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f83877ac7d9bff6e205d2298a4ff92c4
https://doi.org/10.1158/0008-5472.can-12-4174
https://doi.org/10.1158/0008-5472.can-12-4174
Autor:
Andrew Wilson, Olga Efimova, Sabina Swierczek, Todd W. Kelley, Soo Jin Kim, Josef T. Prchal, Magdalena Kovacsovics-Bankowski
Publikováno v:
Experimental Hematology & Oncology
Background Pegylated-interferon alpha (PegINFα) treatment of patients with polycythemia vera (PV) and essential thrombocythemia (ET) has resulted in long-term clinical response, decreased JAK2 V617F allelic burden and restoration of polyclonal hemat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf328e5b5fb3cc7798063a0b69c4f20
https://doi.org/10.1186/s40164-016-0057-y
https://doi.org/10.1186/s40164-016-0057-y
Autor:
Andrew D. Weinberg, Walter J. Urba, Nicholas P. Morris, Brendan D. Curti, Magdalena Kovacsovics-Bankowski
Publikováno v:
Immunological Reviews. 244:218-231
OX40 (CD134) is a tumor necrosis factor (TNF) receptor expressed primarily on activated CD4(+) and CD8(+) T cells and transmits a potent costimulatory signal when engaged. OX40 is transiently expressed after T-cell receptor engagement and is upregula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05d0cd1b79d54ee9258b9f1e912b140b
https://doi.org/10.1111/j.1600-065x.2011.01069.x
https://doi.org/10.1111/j.1600-065x.2011.01069.x
Autor:
Tarsem Moudgil, Levi D. Maston, Magdalena Kovacsovics-Bankowski, M.R. Crittenden, Michael J. Gough, Bernard A. Fox, Sachin Puri, Walter J. Urba, Brendan D. Curti, Andrew D. Weinberg, Christian H. Poehlein, Yuhuan Li, Chris Twitty, Hong-Ming Hu, Shawn M. Jensen, William L. Redmond, Edwin B. Walker, Carl E. Ruby, Nicholas P. Morris
Publikováno v:
Seminars in Oncology. 37:524-532
The existence of tumor-specific T cells, as well as their ability to be primed in cancer patients confirms that the immune response can be deployed to combat cancer. However, there are obstacles that must be overcome to convert the ineffective immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d6b20fdef4e720bc813acc505b023ff
https://doi.org/10.1053/j.seminoncol.2010.09.013
https://doi.org/10.1053/j.seminoncol.2010.09.013